EX 76545
Alternative Names: EX-76545Latest Information Update: 28 Dec 2023
At a glance
- Originator Boehringer Ingelheim Pharmaceuticals
- Class Antifibrotics
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Hepatic-fibrosis in USA
- 08 Nov 2019 Preclinical trials in Hepatic fibrosis in USA (Unspecified route) before February 2020
- 08 Nov 2019 Pharmacodynamics data from preclinical trials in Hepatic fibrosis presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2019)